Recursion Pharmaceuticals Inc (RXRX NASDAQ) stock market data APIs
$5.0615
-0.28(-5.5%)
as of June 18, 2025
Try our APIs with
free plan!
Recursion Pharmaceuticals Inc Financial Data Overview
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Prev. Close
5.0615
Open
4.7825
High
5.29
Low
4.8063
52 wk Range
3.79-12.36
Market Cap
2 077 M
Shares Outstanding
400 M
Revenue
59 790 K
EPS
-0.5
Beta
0.833
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Recursion Pharmaceuticals Inc data using free add-ons & libraries
Get Recursion Pharmaceuticals Inc Fundamental Data
Recursion Pharmaceuticals Inc Fundamental data includes:
- Net Revenue: 59 790 K
- EBITDA: -525 584 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-07
- EPS/Forecast: -0.516
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Recursion Pharmaceuticals Inc News
New
Recursion Pharmaceuticals price target lowered to $5 by Morgan Stanley
Morgan Stanley reduced its price target on Recursion Pharmaceuticals (NASDAQ:RXRX) stock to $5.00 from $8.00 on Monday, while maintaining an Equalweight rating on the shares. According to InvestingP...
Is This Beaten-Down Cathie Wood Artificial Intelligence (AI) Stock a Buy?
Key Points Recursion could help revolutionize the way drugs are developed. Its approach would help cut costs and launch medicines faster. Yet, the company has yet to prove itself and remains a risky ...
Insmed surges on lung drug data; Recursion cuts staff
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Today, a brief rundown of news involving Insmed and R...
Recursion Pharma to reduce workforce by 20%
[Company downsizing, staff reduction and layoffs.] cagkansayin Shares of Recursion Pharmaceuticals (NASDAQ:RXRX [https://seekingalpha.com/symbol/RXRX]) traded higher in the premarket on Tuesday after...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
